Inhaled Pharmacotherapy for Stable COPD: The 2025 GOLD Report

A new recommendation to de-escalate inhaled corticosteroid therapy based on eosinophil counts or adverse events is a welcome change.

Sponsoring Organization: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Diseases (GOLD)

Background

GOLD guidelines on managing chronic obstructive pulmonary disease (COPD) are published annually. Here, we focus on important updates on inhaled pharmacotherapy for stable COPD in the 2025 report. These recommendations also are presented in a recent clinical guideline synopsis in JAMA.

Key Points

Clinicians should use the ABE scale* to initiate treatment based on commonly used symptom severity scoring calculators (CAT or mMRC) and frequency of “moderate” exacerbations (i.e., requiring short-acting bronchodilators and oral corticosteroids).
Patients in GOLD Group A should receive initial monotherapy with a l…

Reviewing Author

Gerald L. Weinhouse, MD

Disclosures

Nothing to disclose

Gerald L. Weinhouse, MD

Disclosures

Nothing to disclose

Inhaled Pharmacotherapy for Stable COPD: The 2025 GOLD Report

Topics

Background

Key Points

Reviewing Author